Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors.
Frontiers in immunology（2023）
摘要
https://clinicaltrials.gov/ct2/home, identifier NCT04569916.
更多查看译文
关键词
advanced solid tumors,anti-angiogenic therapy,clinical trial,immunotherapy,liposomal irinotecan,radiotherapy
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要